FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362541323> ?p ?o ?g. }

• W4362541323 endingPage "2797" @default.
• W4362541323 startingPage "2797" @default.
• W4362541323 abstract "Abstract Background: Pembrolizumab (Pemb) is a key drug for the treatment of advanced or recurrent non-small cell lung cancer (NSCLC). However, there are limited data on Pemb use in older adults aged &gt;75 years with NSCLC, especially in terms of pharmacokinetics (PK). Methods: This open-label multicenter observational study aimed to evaluate real-world data on the safety, efficacy, and blood concentrations of Pemb (both monotherapy and combination therapies) in older adults with NSCLC. Blood samples for PK analysis were collected immediately before Pemb administration. Quantitative Pemb concentrations were measured by liquid chromatography-mass spectrometry. Results: We enrolled 100 patients from July 2019 to September 2020; one patient was excluded due to stage migration. Patient characteristics were as follows: median age, 78 (75-87) years; male/female ratio, 70/29; performance status (PS) 0-1/2-3, 85/14; adenocarcinoma/squamous cell carcinoma/others, 62/25/12; stage I-III/IV/postoperative recurrence (TNM 7th edition), 9/60/30; PD-L1 TPS &lt;1%/1%-49%/≥50%, 12/31/48; and monotherapy/combination therapy, 65/34. The best overall efficacy was CR/PR/SD/PD (7/40/32/20), and the response rate was 47.5%. The median progression-free survival (PFS) and overall survival (OS) were 8.0 and 19.0 months, respectively. The adverse event profile was generally similar to that reported in previous studies. In total, 77 blood samples were collected immediately before the second cycle (C1 trough). Although no clear association between Pemb concentrations and patient background was found, PFS and OS were significantly shortened in the population with low C1 trough, a population characterized by lower PS, high number of metastatic organs at the beginning of treatment, and low blood albumin level. Conclusion: In older adults aged &gt;75 years with NSCLC and low albumin levels and PS and a high number of metastatic organs, C1 trough of Pemb is reduced and not expected to prolong PFS and OS. Citation Format: Yoshiro Nakahara, Kageaki Watanabe, Yukio Hosomi, Yuta Yamanaka, Takayasu Kurata, Hidehito Horinouchi, Yuichiro Ohe, Tetsuhiko Asao, Sho Saeki, Yukari Tsubata, Yu Fujita, Jun Sakakibara Konishi, Hidenori Mizugaki, Mayu Ohuchi, Shigehiro Yagishita, Akinobu Hamada. Multicenter pharmacokinetic study of pembrolizumab for non-small cell lung cancer in older adults aged over 75 years [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2797." @default.
• W4362541323 created "2023-04-06" @default.
• W4362541323 creator A5001014240 @default.
• W4362541323 creator A5004542953 @default.
• W4362541323 creator A5011820456 @default.
• W4362541323 creator A5015850178 @default.
• W4362541323 creator A5048774437 @default.
• W4362541323 creator A5049480854 @default.
• W4362541323 creator A5051036952 @default.
• W4362541323 creator A5054377495 @default.
• W4362541323 creator A5054884728 @default.
• W4362541323 creator A5054929376 @default.
• W4362541323 creator A5057547782 @default.
• W4362541323 creator A5060510665 @default.
• W4362541323 creator A5068435121 @default.
• W4362541323 creator A5069589468 @default.
• W4362541323 creator A5089600181 @default.
• W4362541323 creator A5091200904 @default.
• W4362541323 date "2023-04-04" @default.
• W4362541323 modified "2023-10-16" @default.
• W4362541323 title "Abstract 2797: Multicenter pharmacokinetic study of pembrolizumab for non-small cell lung cancer in older adults aged over 75 years" @default.
• W4362541323 doi "https://doi.org/10.1158/1538-7445.am2023-2797" @default.
• W4362541323 hasPublicationYear "2023" @default.
• W4362541323 type Work @default.
• W4362541323 citedByCount "0" @default.
• W4362541323 crossrefType "journal-article" @default.
• W4362541323 hasAuthorship W4362541323A5001014240 @default.
• W4362541323 hasAuthorship W4362541323A5004542953 @default.
• W4362541323 hasAuthorship W4362541323A5011820456 @default.
• W4362541323 hasAuthorship W4362541323A5015850178 @default.
• W4362541323 hasAuthorship W4362541323A5048774437 @default.
• W4362541323 hasAuthorship W4362541323A5049480854 @default.
• W4362541323 hasAuthorship W4362541323A5051036952 @default.
• W4362541323 hasAuthorship W4362541323A5054377495 @default.
• W4362541323 hasAuthorship W4362541323A5054884728 @default.
• W4362541323 hasAuthorship W4362541323A5054929376 @default.
• W4362541323 hasAuthorship W4362541323A5057547782 @default.
• W4362541323 hasAuthorship W4362541323A5060510665 @default.
• W4362541323 hasAuthorship W4362541323A5068435121 @default.
• W4362541323 hasAuthorship W4362541323A5069589468 @default.
• W4362541323 hasAuthorship W4362541323A5089600181 @default.
• W4362541323 hasAuthorship W4362541323A5091200904 @default.
• W4362541323 hasConcept C112705442 @default.
• W4362541323 hasConcept C121608353 @default.
• W4362541323 hasConcept C126322002 @default.
• W4362541323 hasConcept C143998085 @default.
• W4362541323 hasConcept C197934379 @default.
• W4362541323 hasConcept C2776256026 @default.
• W4362541323 hasConcept C2777701055 @default.
• W4362541323 hasConcept C2778375690 @default.
• W4362541323 hasConcept C2780057760 @default.
• W4362541323 hasConcept C71924100 @default.
• W4362541323 hasConcept C90924648 @default.
• W4362541323 hasConceptScore W4362541323C112705442 @default.
• W4362541323 hasConceptScore W4362541323C121608353 @default.
• W4362541323 hasConceptScore W4362541323C126322002 @default.
• W4362541323 hasConceptScore W4362541323C143998085 @default.
• W4362541323 hasConceptScore W4362541323C197934379 @default.
• W4362541323 hasConceptScore W4362541323C2776256026 @default.
• W4362541323 hasConceptScore W4362541323C2777701055 @default.
• W4362541323 hasConceptScore W4362541323C2778375690 @default.
• W4362541323 hasConceptScore W4362541323C2780057760 @default.
• W4362541323 hasConceptScore W4362541323C71924100 @default.
• W4362541323 hasConceptScore W4362541323C90924648 @default.
• W4362541323 hasIssue "7_Supplement" @default.
• W4362541323 hasLocation W43625413231 @default.
• W4362541323 hasOpenAccess W4362541323 @default.
• W4362541323 hasPrimaryLocation W43625413231 @default.
• W4362541323 hasRelatedWork W2074207917 @default.
• W4362541323 hasRelatedWork W2285479586 @default.
• W4362541323 hasRelatedWork W2981540799 @default.
• W4362541323 hasRelatedWork W3041652591 @default.
• W4362541323 hasRelatedWork W4205587618 @default.
• W4362541323 hasRelatedWork W4286293786 @default.
• W4362541323 hasRelatedWork W4296087748 @default.
• W4362541323 hasRelatedWork W4366822339 @default.
• W4362541323 hasRelatedWork W4379260174 @default.
• W4362541323 hasRelatedWork W4386083912 @default.
• W4362541323 hasVolume "83" @default.
• W4362541323 isParatext "false" @default.
• W4362541323 isRetracted "false" @default.
• W4362541323 workType "article" @default.